Doctors in the Philippines said patients suffering from pterygium, a growth on the surface of the eye, should seek medical ...

The US Food and Drug Administration has issued a warning letter to Cipla after receiving thousands of complaints of defective products in the last couple of years. In the warning letter issued on ...

Drugmaker Cipla expects to put the “slow seasonal growth” of its ‘One India’ business in the last quarter behind it, even as it looks to resolve supply issues involving its generic ...

Glaucoma occurs due to optic nerve damage. A common treatment is prescription eye drops. Although eye drops do not cure or reverse vision loss, they can help prevent optic nerve damage.

Our expert, award-winning staff selects the products we cover and rigorously researches and tests our top picks. If you buy through our links, we may get a commission. I'm a Fitness & Nutrition ...

Eye drops are an early course of treatment to soothe tired and dry eyes, with plenty of over-the-counter options ready to ...

To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...

To check the cornea, they might use yellow dye (fluorescein). You might get the dye in an eye drop, or the doctor might touch a small strip of paper to your eye. When you blink, your tears will ...

This pattern led to a significant price decline, as the stock corrected by around 83 points, translating to a drop of approximately ... basis to manage risk. Cipla encountered resistance around ...

Cipla shares surged 9.88% after USFDA gave Goa facility VAI status. VAI status crucial for Cipla's new launches like Abraxane generic. Stock traded above some SMAs; RSI at 45.75 indicates neutral ...

Cipla (CIPL.NS), opens new tab fell 4% on the day, taking its post-results drop to about 6% over two sessions. Several brokerages cut their earnings estimates for the drugmaker, citing likely ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...